Epstein-Barr virus and the origin of hodgkin lymphoma

Chinese Journal of Cancer

Volumn 33, Issue 12, 2014, Pages 591-597

  Vockerodt, Martina ^a   Cader, Fathima Zumla ^a   Shannon Lowe, Claire ^a   Murray, Paul ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Chronic inflammation; Epstein Barr virus; Hodgkin lymphoma

Indexed keywords

EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HODGKIN DISEASE; HUMAN; REED STERNBERG CELL; VIROLOGY;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; REED-STERNBERG CELLS;

EID: 84909967045     PISSN: None     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10193     Document Type: Review

References (82)

1. [1] Wang S, Medeiros LJ, Xu-Monette ZY, et al. Epstein-Barr viruspositive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol, 2014,18:203-209.
2. [2] Huppmann AR, Nicolae A, Slack GW, et al. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol, 2014,38:316-324.
3. [3] Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A, 1994,91:10962-10966.
4. [4] Kanzler H, Küppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med, 1996,184:1495-1505.
5. [5] Re D, Muschen M, Ahmadi T, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res, 2001,61:2080-2084.
6. [6] Jundt F, Kley K, Anagnostopoulos I, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood, 2002,99:3060-3062.
7. [7] Torlakovic E, Tierens A, Dang HD, et al. The transcription factor PU.1, necessary for B-cell development, is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol, 2001,159:1807-1814.
8. [8] Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood, 2000,95:1443-1450.
9. [9] Jox A, Zander T, Kuppers R, et al. Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells. Blood, 1999,93:3964-3972.
10. [10] Theil J, Laumen H, Marafioti T, et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood, 2001,97:3191-3196.
11. [11] Ushmorov A, Ritz O, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphomaderived cell lines contributes to the loss of immunoglobulin expression. Blood, 2004,104:3326-3334.
12. [12] Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineagespecific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood, 2003,101:1505-1512.
13. [13] Renne C, Martin-Subero JI, Eickernjager M, et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol, 2006,169:655-664.
14. [14] Mathas S, Janz M, Hummel F, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol, 2006,7:207-215.
15. [15] Levine PH, Ablashi DV, Berard CW, et al. Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer, 1971,27:416-421.
16. [16] Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med, 1989,320:689-695.
17. [17] Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med, 1989,320:502-506.
18. [18] Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer, 1990,46:801-804.
19. [19] Anagnostopoulos I, Herbst H, Niedobitek G, et al. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood, 1989,74:810-816.
20. [20] Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer, 1997,70:375-382.
21. [21] Cader FZ, Kearns P, Young L, et al. The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. Cancer Treat Rev, 2010,36:348-353.
22. [22] Jarrett RF, Gallagher A, Jones DB, et al. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. J Clin Pathol, 1991,44:844-848.
23. [23] Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia, 1998,12:1272-1276.
24. [24] Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol, 2003,27:16-26.
25. [25] Oyama T, Yamamoto K, Asano N, et al. Age-related EBV associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res, 2007,13:5124-5132.
26. [26] Rowe M, Fitzsimmons L, Bell AI. Epstein-Barr virus and Burkitt’s lymphoma. Chin J Cancer, 2014,33:609-619.
27. [27] Brauninger A, Spieker T, Willenbrock K, et al. Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptordeficient) Epstein-Barr virus-infected B cells in angioimmunoblastic T cell lymphoma. J Exp Med, 2001,194:927-940.
28. [28] Bechtel D, Kurth J, Unkel C, et al. Transformation of BCR-deficient germinal center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and post transplant lymphoma. Blood, 2005,106:4345-4350.
29. [29] Mancao C, Altmann M, Jungnickel B, et al. Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood, 2005,106:4339-4344.
30. [30] Chaganti S, Bell AI, Begue-Pastor N, et al. Epstein-Barr virus infection in vitro can rescue germinal centre B cells with inactivated immunoglobulin genes. Blood, 2005,106:4249-4252.
31. [31] Young LS, Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer, 2014,33:581-590.
32. [32] Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol, 2001,1:75-82.
33. [33] Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med, 2004,350:1328-1337.
34. [34] Thorley-Lawson DA, Duca KA, Shapiro M. Epstein-Barr virus: a paradigm for persistent infection—for real and in virtual reality. Trends Immunol, 2008,29:195-201.
35. [35] Niedobitek G, Kremmer E, Herbst H, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood, 1997,90:1664-1672.
36. [36] Murray PG, Young LS, Rowe M, et al. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol, 1992,166:1-5.
37. [37] Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science, 1999,286:300-303.
38. [38] Rastelli J, Homig-Holzel C, Seagal J, et al. LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. Blood, 2008,111:1448-1455.
39. [39] Vockerodt M, Morgan SL, Kuo M, et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J Pathol, 2008,216:83-92.
40. [40] Huen DS, Henderson SA, Croom-Carter D, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NFkappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene, 1995,10:549-560.
41. [41] Kieser A, Kilger E, Gires O, et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J, 1997,16:6478-6485.
42. [42] Gires O, Zimber-Strobl U, Gonnella R, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J, 1997,16:6131-6140.
43. [43] Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest, 1997,100:2961-2969.
44. [44] Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood, 2001,98:762-770.
45. [45] Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood, 2002,99:618-626.
46. [46] Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol, 2005,205:498-506.
47. [47] Brielmeier M, Mautner J, Laux G, et al. The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J Gen Virol, 1996,77:2807-2818.
48. [48] Caldwell RG, Wilson JB, Anderson SJ, et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity, 1998,9:405-411.
49. [49] Caldwell RG, Brown RC, Longnecker R. Epstein-Barr virus LMP2Ainduced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol, 2000,74:1101-1113.
50. [50] Engels N, Merchant M, Pappu R, et al. Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module. J Exp Med, 2001,194:255-264.
51. [51] Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol, 2004,5:317-327.
52. [52] Engels N, Yigit G, Emmerich CH, et al. Epstein-Barr virus LMP2A signalling in statu nascendi mimics a B cell antigen receptor-like activation signal. Cell Commun Signal, 2012,10:9.
53. [53] Portis T, Dyck P, Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood, 2003,102:4166-4178.
54. [54] Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene, 2004,23:8619-8628.
55. [55] Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol, 2005,79:1296-1307.
56. [56] Schaadt E, Baier B, Mautner J, et al. Epstein-Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation. J Gen Virol, 2005,86:551-559.
57. [57] Prince S, Keating S, Fielding C, et al. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol, 2003,77:5000-5007.
58. [58] Vrzalikova K, Vockerodt M, Leonard S, et al. Down-regulation of BLIMP1alpha by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood, 2011,117:5907-5917.
59. [59] Yates JL. EBV DNA replication: how do viral genomes become amplified during latent infection? Tursz T, Pagano JS, Ablashi DV, et al. (eds). The Epstein-Barr virus and associated diseases. John Libbey Eurotext, 1993.
60. [60] Vockerodt M, Wei W, Nagy E, et al. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle. J Pathol, 2013,230:399-409.
61. [61] Uccini S, Monardo F, Stoppacciaro A, et al. High frequency of Epstein-Barr virus genome detection in Hodgkin's disease of HIVpositive patients. Int J Cancer, 1990,46:581-585.
62. [62] Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer, 2003, 98:300-309.
63. [63] Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood, 2006, 108:3786-3791.
64. [64] Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood, 2011,118:44-49.
65. [65] Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol, 2009,27:884-890.
66. [66] Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIVinfected population in the United States. J Natl Cancer Inst, 2011,103:753-762.
67. [67] Goedert JJ, Bower M. Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection. Curr Opin Oncol, 2012, 24:531-536.
68. [68] Kowalkowski MA, Mims MP, Amiran ES, et al. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One, 2013,8:e77409.
69. [69] Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma, 2000,38:363-371.
70. [70] Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol, 2008,173:195-204.
71. [71] Küppers R. New insights in the biology of Hodgkin lymphoma. Hematology, 2012,2012:328-334.
72. [72] Piriou ER, van Dort K, Nanlohy NM, et al. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol, 2004,172:6931-6937.
73. [73] Rickinson AB. Co-infections, inflammation and oncogenesis: future directions for EBV research. Semin Cancer Biol, 2014,26:99-115.
74. [74] Kis LL, Salamon D, Persson EK, et al. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc Natl Acad Sci U S A, 2010,107:872-877.
75. [75] Nagy N, Adori M, Rasul A, et al. Soluble factors produced by activated CD4+ T cells modulate EBV latency. Proc Natl Acad Sci U S A, 2012,109:1512-1517.
76. [76] Rowe M, Raithatha S, Shannon-Lowe C. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions. J Virol, 2014, in press.
77. [77] Anderson LJ, Longnecker R. EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. J Gen Virol, 2008,89:1563-1568.
78. [78] Anderson LJ, Longnecker R. Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood, 2009,113:108-116.
79. [79] Crocker J, Overton SP, Smith PJ. Type IV collagen in Hodgkin's disease. An immunohistochemical study. Am J Clin Pathol, 1988, 89:57-62.
80. [80] Poppema S, Potters M, Emmens R, et al. Immune reactions in classical Hodgkin's lymphoma. Sem Hematol, 1999,36:253-259.
81. [81] Enblad G, Molin D, Glimelius I, et al. The potential role of innate immunity in the pathogenesis of Hodgkin's lymphoma. Hematol Oncol Clin North Am, 2007,21:805-823.
82. [82] Cader FZ, Vockerodt M, Bose S, et al. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagenmediated activation of DDR1. Blood, 2013,122:4237-4245.